BioArctic
212,8
SEK
+5,45 %
Mindre end 1K følgere
BIOA B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
+5,45%
-3,1%
+6,67%
+18,09%
+21,95%
-11,33%
+112,8%
+211,79%
+633,79%
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Læs mereMarkedsværdi
18,84 mia. SEK
Aktieomsætning
54,95 mio. SEK
Omsætning
257,35 mio.
EBIT %
-88,79 %
P/E
-
Udbytteafkast, %
-
Finanskalender
21.5
2025
Delårsrapport Q1'25
22.5
2025
Generalforsamling '25
28.8
2025
Delårsrapport Q2'25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
BioArctic: Therapeutic Goods Administration decides not to register lecanemab in Australia
Number of shares and votes in BioArctic AB (publ) as of February 28, 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioArctic: The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
Redeye: BioArctic - A bit stronger Q4 than expected, BMS deal a validation of BT technology
BioArctic: Leqembi® sales reaches €200 million - first sales milestone achieved
